Activation of these alloreactive CD8+ T cells occurs at much higher precursor frequencies than tumor antigen-specific T cells in combination with breaking immune tolerance via mismatched allo-antigens, which results in a robust bystander activation of dendritic cells and inflammatory cytokine production, converting the tumor microenvironment into a more immunostimulatory setting [161]. The gene discussed is CD8A; the disease is neoplasm.